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The cellular and humoral mechanisms accounting for osteolysis in skeletal metastases of malignant melanoma are uncertain.
Osteoclasts, the specialised multinucleated cells that carry out bone resorption, are derived from monocyte/macrophage precursors.
We isolated tumour-associated macrophages (TAMs) from metastatic (lymph node/skin) melanomas and cultured them in the
presence and absence of osteoclastogenic cytokines and growth factors. The effect of tumour-derived fibroblasts and melanoma cells
on osteoclast formation and resorption was also analysed. Melanoma TAMs (CD14þ/CD51 ) differentiated into osteoclasts
(CD14 /CD51þ) in the presence of receptor activator for nuclear factor kB ligand (RANKL) and macrophage-colony stimulating
factor. Tumour-associated macrophage-osteoclast differentiation also occurred via a RANKL-independent pathway when TAMs
were cultured with tumour necrosis factor-a and interleukin (IL)-1a. RT–PCR showed that fibroblasts isolated from metastatic
melanomas expressed RANKL messenger RNA and the conditioned medium of cultured melanoma fibroblasts was found to be
capable of inducing osteoclast formation in the absence of RANKL; this effect was inhibited by the addition of osteoprotegerin
(OPG). We also found that cultured human SK-Mel-29 melanoma cells produce a soluble factor that induces osteoclast
differentiation; this effect was not inhibited by OPG. Our findings indicate that TAMs in metastatic melanomas can differentiate into
osteoclasts and that melanoma fibroblasts and melanoma tumour cells can induce osteoclast formation by RANKL-dependent and
RANKL-independent mechanisms, respectively.
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In the past decade, there has been a substantial increase in the
incidence of cutaneous melanoma in the Caucasian population;
the incidence of melanoma is increasing faster than any other
cancer and the number of deaths from melanoma has increased
throughout the world. Osseous metastases from melanoma are
more common than is generally recognised; most occur in the
axial skeleton and cause bone pain, neurological symptoms and
pathological fractures (DeBoer et al, 1996; Collaborative Ocular
Melanoma Study Group, 2001).
Metastatic lesions from melanoma are usually osteolytic. The
cellular and molecular mechanisms underlying this tumour
osteolysis are poorly understood. Tumour cells are incapable
of lacunar bone resorption and tumour osteolysis is produced
by osteoclasts, multinucleated cells, which are specialised to carry
out lacunar bone resorption (Mundy, 1991; Clohisy et al, 2000).
Osteoclasts are part of the mononuclear phagocyte system, and
are formed by fusion of mononuclear precursors of haemato-
poietic origin (Blair and Athanasou, 2004). Mononuclear osteoclast
precursors circulate in the monocyte fraction and express a
monocyte/macrophage antigenic phenotype (Fujikawa et al, 1996;
Blair and Athanasou, 2004). Osteoclast differentiation from these
mononuclear precursors requires the presence of macrophage-
colony stimulating factor (M-CSF) and involves a receptor–ligand
interaction between osteoclast precursors, which express the
receptor activator for nuclear factor kB (RANK), and cells in
bone (e.g. osteoblasts) which express its ligand (RANKL); this
process is inhibited by osteoprotegerin (OPG), which is produced
by osteoblasts and other cell types (Simonet et al, 1997;
Yasuda et al, 1998; Hofbauer et al, 2000). In addition to this
RANKL-dependent mechanism of osteoclast formation, it has been
shown that several cytokines and growth factors, including
tumour necrosis factor-a (TNF-a), interleukin 6 (IL-6), interleukin
8 (IL-8) and transforming growth factor-b (TGF-b), can induce
osteoclast formation from marrow and circulating osteoclast
precursors by a RANKL-independent mechanism (Kobayashi
et al, 2000; Kudo et al, 2002; Bendre et al, 2003; Kudo et al,
2003; Itonaga et al, 2004).
A prominent macrophage infiltrate is commonly found in many
primary and secondary cancers (Bugelski et al, 1987; Van
Ravenswaay Classen et al, 1992). It has been shown that tumour-
associated macrophages (TAMs) are capable of osteoclast differ-
entiation when these mononuclear phagocytes are co-cultured
with bone-derived stromal cells (Quinn et al, 1998). In this study,
our aim has been to determine the cellular mechanisms of tumour
osteolysis associated with metastatic melanoma. We have
examined whether TAMs in secondary melanomas are capable of
differentiating into osteoclasts and determined whether this occurs
by a RANKL-dependent or RANKL-independent mechanism.
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sites of skeletal metastasis of a melanoma, and we have therefore
also sought to analyse the manner in which these cells might
influence osteoclast formation and resorption.
MATERIALS AND METHODS
This study was approved by the Oxford Clinical Research Ethics
Committee. Alpha minimum essential medium (MEM) and
heat-inactivated foetal bovine serum (FBS) were purchased from
Gibco Laboratories (Paisley, UK). Minimum essential medium
containing 10% FBS, 100Uml
 1 penicillin and 10mgml
 1 strepto-
mycin (MEM/FBS) was used for all cell culture experiments unless
otherwise specified. Macrophage-colony stimulating factor, TNF-a,
OPG, RANK:Fc and antibodies to TNF-a (TNFSF1A), TGF-b RII,
IL-8 (CXCL8) and gp130 were obtained from R&D Systems Europe
(Abingdon, UK). Soluble RANKL was obtained from Peprotech
(London, UK). The human melanoma cell line SK-Mel-29 (Ogg
et al, 2000) was kindly provided by Professor V Cerundolo
(Weatherall Institute of Molecular Medicine, Oxford, UK). All
reagents used in reverse transcription and DNA amplification were
obtained from Invitrogen (Paisley, UK). All experiments were
incubated at 371C in a humidified atmosphere of 5% CO2 and 95%
air, and carried out in triplicate.
TAMs: Isolation and culture
Tissue from six cases of secondary melanoma (five cutaneous and
one lymph node metastasis) was obtained at the time of surgery at
the Radcliffe Infirmary, Oxford. The five male and one female
patients, all Caucasians, were aged between 57 and 83 years, and all
had Stage 3 disease or more at the time of surgery.
The tumour tissue was washed in sterile phosphate-buffered
saline. Fragments of the tumour were then placed in 1mgml
 1 of
collagenase Type 1 (Sigma-Aldrich, Dorset, UK) and incubated for
1h. The digested tissue suspension was passed through a Falcon
s
70mm pore size cell strainer (Becton Dickinson, Oxford, UK). The
filtrate was centrifuged at 1800g for 10min and the cell pellet
suspended in 2ml of MEM/FBS. The cell yield was counted in a
haemocytometer after lysis of red blood cells with 5% (vv
 1) acetic
acid. 1 10
5 cells per well were added to dentine slices and glass
coverslips in a 96-well tissue culture plate. After 3-h incubation,
the dentine slices and glass coverslips were washed in MEM/FBS
to remove any nonadherent cells and were then transferred into
24-well tissue culture plates containing 1ml of MEM/FBS
supplemented with one of the following factors:
1. No added factors (negative control).
2. M-CSF (25ngml
 1).
3. M-CSF (25ngml
 1) and RANKL (30ngml
 1).
4. M-CSF (25ngml
 1), TNF-a (20mgml
 1, day 4–21 of culture)
and IL-1a (10ngml
 1, day 11–21 of culture).
Cultures on coverslips and dentine slices were maintained for 14
and 21 days, respectively, with culture medium and factors
replenished every 3–4 days.
Isolation of human peripheral blood mononuclear
cells (PBMCs)
Human monocytes were obtained by density gradient centrifuga-
tion of 50ml of buffy coat cell preparation provided by the
National Blood Transfusion Service (Bristol, UK). The buffy coat
preparation was mixed with an equal volume of MEM and purified
over Histopaque (Sigma-Aldrich, Dorset, UK). After centrifugation
at 2250g for 25min, the cell layer above the Histopaque was
collected, suspended in MEM, and centrifuged at 1800g for 10min.
The cell pellet was resuspended in MEM and centrifuged again.
5ml of MEM/FBS was then added to the cell pellet and the number
of cells counted in a haematocytometer following lysis of red blood
cells with 5% (vv
 1) acetic acid. 5 10
5 cells per well were plated
immediately onto dentine slices and glass coverslips in 96-well
tissue culture plates with 100ml per well of MEM/FBS. After 3-h
incubation, the dentine slices and glass coverslips were washed in
MEM/FBS to remove any nonadherent cells, and transferred into
24-well tissue culture plates containing 1ml of MEM/FBS and
M-CSF (25ngml
 1). Positive controls were set up in the presence
of M-CSF (25ngml
 1) and soluble RANKL (30ngml
 1).
Cytochemical and functional assessment of osteoclast
formation
Histochemistry for the expression of the osteoclast-associated
enzyme, tartrate-resistant acid phosphatase (TRAP), was carried
out on cell cultures on coverslips using a commercially available
kit (Sigma-Aldrich, Dorset, UK). Cell preparations were fixed in
citrate/acetone solution and stained for acid phosphatase, using
naphthol AS-BI phosphate as a substrate, in the presence of 1.0 M
tartrate (Minkin, 1982). The product was reacted with Fast Garnet
GBC salt and counterstained with haematoxylin. Cell cultures on
glass coverslips were also stained immunohistochemically using
an indirect immunoperoxidase technique with 23C6 (Serotec,
Oxford, UK) and GSR1 (Dakopatts, Glostrup, Denmark) mouse
monoclonal antibodies directed against the vitronectin receptor
(VNR) (Davies et al, 1989; Athanasou and Quinn, 1990) and
CD68 (macrophage and osteoclast marker), respectively. Anti-
bodies directed against the melanoma markers, HMB-45 and S100
(Dakopatts, Glostrup, Denmark) were also employed for pheno-
typic characterisation.
Functional evidence of TAM-osteoclast formation was deter-
mined by a lacunar resorption assay system using cell cultures on
dentine slices (Quinn et al, 1998). After 21 days incubation, the
cells were removed from the dentine slices by treatment with 1 M
ammonium hydroxide. The dentine slices were washed in distilled
water and ultrasonicated to remove adherent cells, then stained
with 0.5% (wv
 1) toluidine blue to reveal areas of lacunar
resorption and examined by light microscopy.
Melanoma-derived fibroblasts: Isolation and culture
After enzyme digestion of the tumour, the cell pellet obtained was
resuspended in MEM/FBS and placed in 25cm
2 tissue culture
flasks. The medium was changed after 24-h incubation and then at
5–7 day intervals. These cultures, containing spindle-shaped
fibroblast-like cells, were passaged when confluent and re-cultured
twice. After passage 2, the cells were cultured for a further 2–3
weeks until confluent; conditioned medium (CM) was then
collected after a further 48-h incubation.
Melanoma-derived fibroblasts: total RNA extraction
and RT–PCR
For RT–PCR studies, the fibroblasts were removed by treatment
with trypsin (0.25%)/EDTA (1mM) solution. Total RNA extrac-
tion was carried out using the RNeasy
s mini kit (QIAGEN, Hom-
brechtikon, Switzerland), according to the manufacturer’s instruc-
tions. Single-strand complementary DNA (cDNA) was synthesised
from 2.0mg of total RNA according to standard protocols using the
SuperScript
s First-Strand Synthesis System for RT—PCR. Com-
plementary DNA was amplified by PCR to generate products
corresponding to messenger RNA (mRNA) encoding human gene
products for GAPDH, RANKL, OPG and TRAIL (Table 1). Aliquots
of PCR products were fractionated on 1% agarose gels stained with
ethidium bromide. Gel pictures and quantification of signals were
obtained after scanning with AlphaImager 2200 (Alpha Innotech
Corporation, USA) and ImageJ software analysis (public domain
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GAPDH, RANKL, OPG and TRAIL was also determined in bone
stromal cells cultured from explants of cancellous bone derived
from the femoral head as previously described (Gundle and
Beresford, 1995). Cultures were passaged at least twice before the
cells were harvested for RT–PCR.
Melanoma-derived fibroblasts: effect on osteoclast
formation
To determine whether melanoma-derived fibroblasts produce
a soluble factor capable of inducing osteoclast formation,
human PBMCs were cultured for 21 days in the presence and
absence of melanoma-derived fibroblast CM. A dose–response
curve (0–10%) established that 10% CM provided the optimal
concentration for osteoclast formation. Subsequent experiments
were set up as follows:
1. M-CSF (25ngml
 1) (negative control).
2. M-CSF (25ngml
 1), RANKL (30ngml
 1) (positive control).
3. 10% CM, M-CSF (25ngml
 1).
4. 10% CM, M-CSF (25ngml
 1), 7OPG (500ngml
 1)o r
RANK:Fc (500ngml
 1).
5. 10% CM, M-CSF (25ngml
 1), 7anti-human TNF-a antibody
(10mgml
 1).
Cultures on coverslips and dentine slices were maintained for 14
and 21 days, respectively, with culture medium, CM and cytokines
replenished every 3–4 days.
SK-Mel-29 melanoma cells: effect on osteoclast formation
SK-Mel-29 cells were cultured in 25cm
2 culture flasks until
confluent; CM was then extracted after further incubation of
48h. A dose–response curve (0–10%) established that 10% CM
provided the optimal concentration for osteoclast formation
(Figure 6). Subsequent experiments with human PBMCs were set
up as follows:
1. M-CSF (25ngml
 1) (negative control).
2. M-CSF (25ngml
 1), RANKL (30ngml
 1) (positive control).
3. M-CSF (25ngml
 1), 10% CM.
4. M-CSF (25ngml
 1), 10% CM, 7OPG (500ngml
 1)o r
RANK:Fc (500ngml
 1).
5. M-CSF (25ngml
 1), 10% CM, 7one of the following: anti-
human TNF-a antibody (10mgml
 1); anti-human TGF-b anti-
body (500ngml
 1); anti-human gp130 antibody (5mgml
 1);
anti-human IL-8 antibody (10mgml
 1).
Peripheral blood mononuclear cell cultures on coverslips
and dentine slices were maintained for 14 and 21 days,
respectively, with culture medium and factors being replenished
every 3–4 days.
SK-Mel-29 melanoma cells: total RNA extraction
and RT–PCR
SK-Mel-29 cells from 25cm
2 culture flasks were removed for RNA
extraction by treatment with trypsin and the same protocol for
RT–PCR and fractionation on agarose gels described above was
used.
SK-Mel-29 melanoma cells: determining the nature
of active moiety within CM
In order to provide information on the nature of the active moiety
present in the SK-Mel-29 CM, the CM was concentrated and the
protein solute separated from low molecular weight compounds
using an Amicon
s Ultra PL-10, 10000 nominal molecular weight
limit (NMWL) centrifugal filter device (Millipore Corp., USA). The
concentrated retentate (X10kDa) was diluted in MEM and the
ultrafiltrate (o10kDa) was added neat to human PBMC cultures
supplemented with M-CSF (25ngml
 1). Cultures on coverslips
and dentine slices were maintained for 14 and 21 days,
respectively, with culture medium and factors replenished every
3–4 days.
SK-Mel-29 melanoma cells: effect on mature osteoclast
activity
In order to determine if SK-Mel-29 CM has any effect on mature
osteoclast activity, osteoclastic giant cells from two specimens of
fresh giant cell tumour of bone were isolated by digestion with
collagenase as previously described (Lau et al, 2005) and cultured
in the presence and absence of SK-Mel-29 CM. Cultures on
coverslips and dentine slices were maintained for 48h.
Statistical analysis
The extent of lacunar resorption was measured using an image
analysis software (Adobe Photoshop, USA) as previously described
(Quinn et al, 1998) and expressed as the mean percentage of
surface area resorbed7standard error of mean (s.e.m.). In order to
minimise the effect of batch-to-batch variation of PBMCs, all
resorption data were normalised and expressed relative to the
response obtained in PBMC cultures incubated with 25ngml
 1
M-CSF and 30ngml
 1 RANKL (positive control). Statistical
significance was determined using the unpaired t-test and
P-values o0.05 were considered significant.
RESULTS
Characterisation of TAMs isolated from melanoma
After incubation for 24h on glass coverslips, the cells isolated from
the metastatic melanomas, when cultured in the presence and
absence of M-CSF and RANKL, strongly expressed the monocyte/
macrophage marker CD14, which is not expressed by osteoclasts.
Table 1 Human primer sequences used in amplification
Primer sequence Size of product (bp) Annealing temp. (1C)
GAPDH Forward 50-CAC TGA CAC GTT GGC AGT GG-30 360 60
Reverse 50-CAT GGA GAA GGC TGG GGC TC-30
OPG Forward 50- ATG AAC AAG TTG CTG TGC TG-30 354 58
Reverse 50-GCA GAA CTC TAT CTC AAG GTA-30
RANKL Forward 50-CAG ATG GAT CCT AAT AGA AT-30 324 56
Reverse 50-ATG GGA ACC AGA TGG GAT GTC-30
TRAIL Forward 50-ATC ATG GCT ATG ATG GAG GT-30 315 58
Reverse 50-AAC TGT AGA AAT GGT TTC CTC-30
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VNR, and the melanoma markers, HMB-45 and S100. Twenty-four
hours culture of these cells on dentine slices, both in the presence
and absence of M-CSF and RANKL, showed no evidence of lacunar
resorption. The melanoma-derived mononuclear cells in long-term
cultures thus expressed the phenotypic markers of macrophages
and not osteoclasts or tumour cells.
TAM–osteoclast differentiation
In the presence of RANKL and M-CSF, numerous multinucleated
cells expressing the osteoclast-associated markers, TRAP and
VNR, were found in 14-day TAM cultures incubated on glass
coverslips (Figure 1). No expression of TRAP or VNR was seen
when M-CSF or RANKL was omitted.
After incubation for 21 days, the TAMs incubated on dentine
slices, in the presence of M-CSF and RANKL, showed functional
evidence of osteoclast differentiation with the formation of
numerous areas of lacunar resorption; these were largely in the
form of single large resorption pits or multiple compound areas of
lacunar excavation on the dentine surface (Figure 2). In the
absence of M-CSF or soluble RANKL, osteoclast formation and
lacunar resorption was not seen.
Tumour-associated macrophages cultured with M-CSF, TNF-a
and IL-1a also showed formation of TRAPþ and VNRþ
multinucleated cells. Functional evidence of osteoclast formation
under these conditions was also noted in 21-day cultures on
dentine slices where a few small single round or ovoid resorption
pits were formed (Figure 3).
Effect of melanoma-derived fibroblasts on osteoclast
formation
After three passages, the cells isolated from the melanomas by
collagenase digestion consisted almost entirely of spindle-shaped,
fibroblastic mononuclear cells, which did not stain for CD14,
CD68, VNR, TRAP, HMB-45 and S100. No multinucleated cells
were present in these cultures. Human PBMCs incubated with
M-CSF and CM derived from these fibroblast cultures showed
evidence of osteoclast formation with formation of TRAPþ and
A
B
Figure 1 (A) TRAP and (B) VNR expression by multinucleated cells
formed in 14-day melanoma TAM cultures in the presence of M-CSF and
RANKL. Bar¼500mm.
Figure 2 Large, compound lacunar resorption pit formed on a dentine
slice in a 21-day melanoma TAM culture in the presence of M-CSF and
RANKL (Toluidine blue staining). Bar¼500mm.
Figure 3 Small, single lacunar resorption pits formed on a dentine slice in
a 21-day melanoma TAM culture in the presence of M-CSF, TNF-a and IL-
1 (Toluidine blue staining). Bar¼400mm.
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formation (Figure 4A). The addition of OPG to these cultures
resulted in a marked decrease in the extent of lacunar resorption in
all cases; this inhibition was statistically significant in three cases
(Figure 4B). The addition of RANK:Fc to these cultures similarly
inhibited osteoclast formation and resorption.
Using a semiquantitative RT–PCR method, signals generated by
mRNA levels of RANKL, OPG and TRAIL were quantified relative
to GAPDH. Expression of RANKL, OPG and TRAIL was noted in
fibroblasts cultured from all melanoma specimens and was also
noted in control bone stromal cells (Figure 5).
Effect of SK-Mel-29 melanoma cells on osteoclast
formation
Cultures of human PBMCs incubated with M-CSF and SK-Mel-29
CM resulted in the formation of TRAPþ and VNRþ multi-
nucleated cells capable of lacunar resorption. The amount of
lacunar resorption was dose-dependent, with maximal resorption
seen at CM concentration of 10% (Figure 6). The addition of OPG
or RANK:Fc to SK-Mel-29 CM-treated PBMC cultures did not
abolish osteoclast formation or significantly inhibit lacunar
resorption, suggesting that SK-Mel-29 CM stimulated osteoclasto-
genesis via a RANKL-independent mechanism. However, the
addition to SK-Mel-29 CM-treated PBMC cultures of neutralising
antibodies to humoral factors known to stimulate osteoclasto4-
genesis, specifically antibodies to the receptors for IL-6/-11
(gp130) and TGF-b, and antibodies to the cytokines TNF-a and
IL-8, also failed to abolish osteoclast formation or significantly
inhibit resorption (Figure 7A).
Cultures of human PBMCs incubated in the presence of M-CSF
and the high molecular weight (X10kDa) SK-Mel-29 CM
retentate, separated using the centrifugal filter device, resulted
in the formation of a small number of TRAPþ multinucleated
cells capable of lacunar resorption. The lacunar resorption pits
produced were similar in appearance to those formed when
unseparated CM was added to PBMC cultures. In PBMC cultures to
which SK-Mel-29 CM ultrafiltrate (o10kDa) was added, TRAPþ
multinucleated cells and lacunar resorption was not seen. This
confirms that the osteoclastogenic activity of the SK-Mel-29 CM is
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Figure 4 (A) Lacunar resorption pits formed on a dentine slice in a
21-day human PBMC culture in the presence of 10% melanoma-derived
fibroblast conditioned medium (CM) (Toluidine blue staining).
Bar¼250mm. (B) Effect of 10% melanoma-derived fibroblast CM from
five patients (M1–M5) on human monocyte–osteoclast differentiation.
The data represent the mean % surface area (SA) lacunar resorption
relative to the positive control (PBMC cultures with M-CSF and RANKL), in
the absence and presence of OPG (500ngml
 1). Error bars denote s.e.m.
(n¼3). *P¼0.02, **P¼0.002.
TRAIL
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RANKL
GAPDH
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Figure 5 Expression of RANKL, OPG and TRAIL mRNA by fibroblasts
derived from melanoma. Reverse transcription–polymerase chain reaction
products were fractionated on agarose gel. Lane 1, positive control; lane 2,
negative control; lane 3, SK-Mel-29; lanes 4–9, melanoma fibroblasts from 6
patients; lanes 10–12, normal bone stromal cells.
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Figure 6 The effect of SK-Mel-29 conditioned medium (CM) on human
monocyte–osteoclast differentiation. The data represent the mean %
surface area (SA) lacunar resorption relative to the positive control (PBMC
cultures with M-CSF and RANKL). Error bars denote s.e.m. (n¼6).
* denotes the significant difference in lacunar resorption in PBMC cultures
incubated in the absence and presence of 10% SK-Mel-29 CM (Po0.01)
relative to untreated control.
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X10kDa. Further confirmation of the active moiety present in
the retentate was seen in cultures of human PBMCs and increasing
concentrations of SK-Mel-29 CM retentate. A dose-dependent
response was seen, with a proportional increase in the formation
of TRAPþ multinucleated cells and lacunar resorption at higher
concentrations of SK-Mel-29 CM retentate (Figure 7B).
RT–PCR studies showed that SK-Mel-29 cells expressed the
mRNA for OPG and TRAIL but not RANKL (Figure 5).
Effect of SK-Mel-29 cells on mature osteoclast activity
Giant cell tumour of bone is characterised morphologically by the
presence of numerous giant cells, which express the cytochemical
and functional phenotypic characteristics of osteoclasts. This effect
was evident in cultures with no added factors, where numerous
TRAPþ and VNRþ multinucleated cells were seen and there was
extensive lacunar excavation of the dentine surface. The addition
of SK-Mel-29 CM did not significantly influence the resorption
activity of the osteoclasts isolated from the giant cell tumour.
DISCUSSION
Bone metastases in melanoma are commonly osteolytic and
associated with marked osteoclastic resorption. In this study, we
have identified a number of cellular and humoral factors that
contribute to osteoclast formation in metastatic melanoma. First,
we have shown that TAMs in metastatic melanomas have the
ability to differentiate into functional mature osteoclasts. This
osteoclast formation is mediated mainly by a RANKL-dependent
mechanism, but TNF-a (and possibly other cytokines/growth
factors) is also capable of inducing osteoclast formation. We also
found that melanoma-derived fibroblasts, like bone stromal cells,
express RANKL mRNA and that these cells support osteoclast
formation by a RANKL-dependent mechanism. In contrast,
melanoma cells produce a soluble factor that appears to promote
osteoclast formation by a mechanism independent of RANKL.
Melanoma cells are known to secrete several factors, which
induce the recruitment of TAMs. These include monocyte
chemotactic protein-1, M-CSF, GM-CSF and VEGF-C (Skobe
et al, 2001). Tumour-associated macrophages form a major
component of the inflammatory cell infiltrate within and around
primary and metastatic melanomas, and TAM numbers have been
shown to correlate with melanoma invasion (Torisu et al, 2000).
These TAMs produce cytokines and growth factors, including IL-8,
VEGF and FGF, which stimulate tumour growth and angiogenesis
in melanomas (Torisu et al, 2000; Nesbit et al, 2001; Shimizu et al,
2001; Callejo et al, 2004). We have previously shown that mouse
and human TAMs isolated from primary and metastatic breast
carcinomas are capable of differentiation into TRAPþ osteoclastic
cells capable of extensive lacunar resorption when these cells are
co-cultured with bone-derived stromal cells and M-CSF (Quinn
et al, 1992, 1994). In this study, we found that melanoma-derived
TAMs are also capable of osteoclast differentiation by a RANKL-
dependent mechanism. Tumour-associated macrophages isolated
from secondary melanomas expressed the monocyte/macrophage
marker CD14 and were negative for the osteoclast markers TRAP
and VNR and incapable of carrying out lacunar resorption.
However, following treatment with RANKL and M-CSF, these cells
differentiated into TRAP
þ and VNR
þ multinucleated cells
capable of extensive lacunar resorption.
Tumor necrosis factor-a and other cytokines/growth factors that
induce osteoclast formation by a RANKL-independent mechanism,
are known to be produced by melanoma cells (Lazar-Molnar
et al, 2000). We found that melanoma TAMs were also capable of
osteoclast differentiation when cultured in the presence of
M-CSF, TNF-a and IL-1. In contrast to the numerous large
multinucleated osteoclasts and extensive areas of lacunar resorp-
tion produced when TAMs were cultured with RANKL, osteoclasts
formed in the presence of TNF-a and IL-1 were much smaller and
contained fewer than four nuclei; resorption areas produced by
these osteoclasts were also correspondingly smaller, being
mainly in the form of single resorption pits. We have previously
demonstrated that this is characteristic of TNF-a and other
cytokine-induced mechanisms of osteoclast differentiation
(Kudo et al, 2002).
Melanoma–stromal cell interactions are known to play an
important role in tumour growth and metastasis. Melanoma cells
are known to produce M-CSF in vitro (Perez et al, 2001, Varney
et al, 2005). As some fibroblast populations are known to express
RANKL and OPG, we investigated whether fibroblasts derived
from secondary melanomas expressed these osteoclastogenic
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Figure 7 (A) The effect of OPG and neutralising antibodies to
osteoclastogenic humoral factors on resorption in PBMC cultures
incubated with M-CSF and 10% SK-Mel-29 conditioned medium (CM).
The data represent the mean % surface area (SA) lacunar resorption
relative to the positive control (PBMC cultures with M-CSF and RANKL).
Error bars denote s.e.m. (n¼6). (B) The effect of the low and high
molecular weight components within SK-Mel-29 CM on human mono-
cyte–osteoclast differentiation. The data represent the mean % surface
area (SA) lacunar resorption relative to the positive control (PBMC cultures
with M-CSF and RANKL). Error bars denote s.e.m. (n¼6). In addition, the
mean number of TRAPþ multinucleated cells (MNC) is also demon-
strated (n¼2).
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sfactors and were capable of supporting osteoclast formation. We
found that melanoma fibroblasts express RANKL, OPG and
TRAIL; the latter is known to bind OPG. We also found that the
addition of CM derived from cultures of these melanoma
fibroblasts could support monocyte–osteoclast differentiation
and that this process was markedly inhibited by the addition of
OPG. Our findings suggest that melanoma fibroblasts may induce
osteoclast formation by a RANKL-dependent mechanism, and that
this most likely occurs through the release of soluble RANKL. This
feature has been reported in fibroblasts found in giant cell tumour
of bone (Lau et al, 2005), a tumour that contains numerous
osteoclasts, but not in normal fibroblast populations, including
skin, bone marrow stromal cells, as well as fibroblasts derived from
other non-neoplastic tissue (Quinn et al, 2000; Sabokbar et al,
2005; Sun et al, 2006). Stromal cells in primary melanoma are
known to stimulate tumour progression and these cells may be
activated in bone metastases to stimulate osteoclast differentiation
and bone resorption (Spatz et al, 2002).
Melanoma cells have previously been shown to stimulate the
recruitment and activation of osteoclasts that carry out malignant
bone resorption (Clohisy et al, 1996). Melanoma cells release a
number of osteoclastogenic factors including TGF-b, IL-6, M-CSF,
GM-CSF and TNF-a (Perez et al, 2001); these cells also upregulate
osteoblast expression of factors known to stimulate RANKL-
dependent osteoclastogenesis. Melanoma cells, however, have not
been shown to express RANKL (Chikatsu et al, 2000), and we did
not identify RANKL mRNA in SK-Mel-29 human melanoma cells.
This is in keeping with our finding that neither OPG nor RANK:Fc
inhibited monocyte–osteoclast differentiation induced by the
addition of melanoma cell CM. The osteoclastogenesis induced
by the soluble factor produced by SK-Mel-29 cells thus appeared to
be RANKL-independent. The molecular weight of this soluble
factor was X10kDa as only the retentate of the CM from the
SK-Mel-29 cells induced osteoclastic formation. Attempts to block
all known humoral factors that have been shown to stimulate
RANKL-independent osteoclast formation by the addition of
neutralising antibodies to TNF-a, IL-6/11, IL-8 and TGF-b alone
inhibited osteoclast formation. Melanoma cells are known to
produce a number of cytokines and growth factors which have
been implicated in osteoclastogenesis, and it is thus possible that
more than one humoral factor produced by SK-Mel-29 cells may
contribute to the induction of osteoclast formation.
In summary, we have shown that the major cellular components
of a metastatic melanoma play an important role in promoting the
osteoclast formation that is required for tumour osteolysis.
TRAPþ osteoclasts can be formed from TAMs in melanoma
metastases and this process appears to occur by both RANKL-
dependent and RANKL-independent mechanisms. The former is
likely to involve an interaction with bone stromal cells and tumour
fibroblasts, both of which express RANKL. Melanoma cells also
produce a soluble factor that stimulates osteoclast formation by
a RANKL-independent mechanism. In early skeletal metastases
where a relatively high macrophage: tumour cell ratio and large
number of osteoclasts are typically found (Galasko, 1976; Bugelski
et al, 1985), RANKL-dependent and RANKL-independent mecha-
nism of pathological bone resorption are likely to play a role in the
establishment of a metastatic malignant melanoma in bone.
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